UTHR United Therapeutics Corporation

+1.85  (+2%)
Previous Close 79.52
Open 80
Price To Book 1.4
Market Cap 3,568,100,701
Shares 43,850,322
Volume 374,170
Short Ratio
Av. Daily Volume 629,001

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 ongoing.
Pulmonary hypertension associated with idiopathic pulmonary fibrosis (WHO Group 3)
Phase 3 data released April 8, 2019 did not meet primary endpoint.
Esuberaprost - BEAT
Pulmonary arterial hypertension (PAH)
Phase 2/3 planned.
Aurora-GT - (eNOS gene therapy)
Pulmonary arterial hypertension (PAH)
Phase 3 data released August 8, 2018. Primary endpoint met.
Pulmonary arterial hypertension (PAH)
Refusal to file Letter (RTF) issued August 31, 2017. NDA resubmitted June 27, 2019.
Pulmonary Arterial Hypertension (PAH)
Approved Dec 20 2013
Oral treprostinil
Pulmonary arterial hypertension (PAH)
Phase 3 ongoing. Licensed to UTHR November 15, 2018.
Pulmonary Arterial Hypertension
Phase 3 portion of trial continues to enroll - noted February 21, 2018.
Unituxin - DISTINCT
Small cell lung cancer

Latest News

  1. Is United Therapeutics Corporation's (NASDAQ:UTHR) CEO Paid Enough Relative To Peers?
  2. Correvio Reports Second Quarter 2019 Financial Results
  3. Edited Transcript of UTHR earnings conference call or presentation 31-Jul-19 1:00pm GMT
  4. Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?
  5. MannKind Corporation (MNKD) Q2 2019 Earnings Call Transcript
  6. Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet
  7. United Therapeutics Corporation To Present At 2019 Wedbush PacGrow Healthcare Conference
  8. United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y
  9. United Therapeutics Corporation (UTHR) 2019 Q2 Earnings Call Transcript
  10. United Therapeutics is executing its growth plan. Why isn’t its stock price higher?
  11. United Therapeutics (UTHR) Q2 Earnings and Revenues Beat Estimates
  12. United Therapeutics Corporation Reports Second Quarter 2019 Financial Results
  13. United Therapeutics Corporation To Report Second Quarter 2019 Financial Results Before The Market Opens On Wednesday, July 31, 2019
  14. What You Should Know About United Therapeutics Corporation's (NASDAQ:UTHR) Financial Strength
  15. Sexual harassment lawsuit against Md. biotech to advance with plaintiff's identity revealed
  16. S&P Makes It Two Record Closes in a Row
  17. Credit Suisse: United Therapeutics Becoming More Fundamentally Driven
  18. United Therapeutics Stock Jumps After Analyst Says Its Slide Was Overdone
  19. Stocks Slide as Fed Dampens Rate Cut Expectations
  20. Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod